Immuron (IMRN) Cash from Financing Activities (2016 - 2024)
Immuron (IMRN) posted quarterly Cash from Financing Activities of -$27401.4 for Q4 2024, down 81.67% year-over-year from -$149453.5 in Q1 2024, and down 81.67% quarter-over-quarter from -$15083.4 in Q4 2023.
Immuron (IMRN) Cash from Financing Activities (2016 - 2024) Analysis & Trends
Immuron's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$27401.4 for Q4 2024.
- In Q4 2024, Cash from Financing Activities fell 81.67% year-over-year to -$27401.4; the TTM figure through Dec 2024 stood at -$62500.5 (down 100.24% YoY), while the FY2025 annual figure was $199747.0, up 23994.93% from the prior year.
- Cash from Financing Activities for Q4 2024 stood at -$27401.4, down from -$15083.4 in the prior quarter.
- The five-year high for Cash from Financing Activities was $26.6 million in Q4 2020, with the low at -$27401.4 in Q4 2024.
- The 5-year median for Cash from Financing Activities is -$15083.4 (2023), against an average of $5.3 million.
- The sharpest annual moves came in 2020 and 2022: Cash from Financing Activities surged 2007.11% in 2020, then plunged 1552.95% in 2022.
- Immuron's Cash from Financing Activities stood at $26.6 million in 2020, then plunged by 99.99% to $1479.4 in 2021, then sank by 1552.95% to -$21495.0 in 2022, then grew by 29.83% to -$15083.4 in 2023, then sank by 81.67% to -$27401.4 in 2024.
- Business Quant data shows IMRN's Cash from Financing Activities at -$27401.4 in Q4 2024, -$15083.4 in Q4 2023, and -$21495.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -27,401.44 |
| Dec 31, 2024 | -27,401.44 |
| Dec 31, 2023 | -15,083.45 |
| Dec 31, 2023 | -15,083.45 |
| Dec 31, 2022 | -21,495.00 |
| Dec 31, 2022 | -21,495.00 |
| Dec 31, 2021 | 1,479.41 |
| Dec 31, 2021 | 1,479.41 |
| Dec 31, 2020 | 26.60 Mn |
| Dec 31, 2020 | 26.60 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2017 | -191,627.87 |
| Dec 31, 2017 | -191,627.87 |
| Dec 31, 2016 | 2.29 Mn |
| Dec 31, 2016 | 2.29 Mn |